Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Oct 2022

Vermij Lisa, Léon-Castillo Alicia, Singh Naveena, Powell Melanie E, Edmondson Richard J, Genestie Catherine, Khaw Pearly, Pyman Jan, McLachlin C Meg, Ghatage Prafull, de Boer Stephanie M, Nijman Hans W, Smit Vincent T H B M, Crosbie Emma J, Leary Alexandra, Creutzberg Carien L, Horeweg Nanda, Bosse Tjalling

Abstract excerpt

Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and the most likely to benefit from adjuvant chemo(radio)therapy. P53abn EC are POLE wildtype, mismatch repair proficient and show abnormal immunohistochemical (IHC) staining for p53. Correct interpretation of routinely performed p53 IHC has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mismatch Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to POLE gene

Share to TP53 gene

Share to Immunohistochemistry

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35752743
DOI: 10.1038/s41379-022-01102-x
PMCID: PMC7613653

Genes

POLE
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.PMID 35752743Read ↗

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.Semantic proximity Read ↗

Endometrial Cancer: Transitioning from Histology to Genomics.Semantic proximity Read ↗

The emerging role of molecular pathology in directing the systemic treatment of endometrial cancerSemantic proximity Read ↗

Molecular testing for endometrial cancer: An SGO clinical practice statement.Semantic proximity Read ↗

Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype.Semantic proximity Read ↗

Incorporation of molecular characteristics into endometrial cancer management.Semantic proximity Read ↗

Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments.Semantic proximity Read ↗

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment DecisionsSemantic proximity Read ↗

Molecular Characterization and Clinical Implications of Endometrial Cancer.Semantic proximity Read ↗

Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification.Semantic proximity Read ↗

Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.Semantic proximity Read ↗

Associations between molecular subtypes and high-risk pathological factors in endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.